Table 3.
Pathological responses tumour stage and molecular subtype (N:45)
| Non‐pCR * N (%) | pCR* N (%) | P‐value | |
|---|---|---|---|
| Overall population | 17 (37.8) | 28 (62.2) | |
| Stage at diagnosis | |||
| II | 8 (50.0) | 8 (50.0) | 0.209 |
| III | 9 (31.0) | 20 (69.0) | |
| Inflammatory | |||
| Yes | 3 (33.3) | 6 (66.7) | 0.99 |
| No | 14 (38.9) | 22 (61.1) | |
| HER2 status | |||
| Amplified | 5 (45.5) | 6 (54.5) | 0.55 |
| Overexpressed | 12 (35.3) | 22 (64.7) | |
| Molecular subtypes | |||
| Luminal B | 12 (50.0) | 12 (50.0) | 0.07 |
| HER2‐enriched | 5 (23.8) | 16 (76.2) | |
| Triple positive tumors | |||
| Yes | 9 (52.9) | 8 (47.1) | 0.09 |
| No | 8 (28.6) | 20 (71.4) | |
| BMI | |||
| <25 | 16 (55.2) | 13 (44.8) | 0.001 |
| ≥25 | 1 (6.2) | 15 (93.8) |
The DECT Trial. BMI, body mass index.
*
Pathological complete response (pCR) was defined as no residual invasive tumor in both breast and axilla.